Enterprise Value

208.6B

Cash

3.174B

Avg Qtr Burn

-289.4M

Short % of Float

0.23%

Insider Ownership

19.85%

Institutional Own.

48.17%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BRUKINSA (zanubrutinib) Details
Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma , Cancer

Approved

Update

BRUKINSA + obinutuzumab Details
Cancer, Follicular lymphoma

Approved

Quarterly sales

TEVIMBRA (tislelizumab) Details
Cancer, Esophageal Squamous Cell Carcinoma

Approved

Quarterly sales

Tislelizumab + chemo Details
Cancer, Gastroesophageal adenocarcinomas

PDUFA

Approval decision

TEVIMBRA (tislelizumab) Details
Esophageal Squamous Cell Carcinoma, Cancer

PDUFA

Approval decision

Ociperlimab (Anti-TIGIT) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Phase 3

Data readout

BRUKINSA + tislelizumab Details
Cancer, Hepatocellular carcinoma

Phase 3

Data readout

Tislelizumab Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Phase 3

Data readout

Ociperlimab (anti-TIGIT Ab) + tislelizumab Details
Cervical cancer, Small cell lung cancer, Non-small cell lung carcinoma, Esophageal Squamous Cell Carcinoma, Cancer

Phase 2

Data readout

Phase 1/2

Data readout

BGB-16673 (BTK CDAC) Details
Cancer, B-cell malignancies

Phase 1

Data readout

BGB-A445 w/ tislelizumab Details
Renal cell carcinoma, Cancer, Bladder cancer, Melanoma

Phase 1

Update